Phase Ib dose-escalation trial of fasoracetam [NFC-1] in mGluR network mutation positive adolescents with attention deficit hyperactivity disorder

Trial Profile

Phase Ib dose-escalation trial of fasoracetam [NFC-1] in mGluR network mutation positive adolescents with attention deficit hyperactivity disorder

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Feb 2016

At a glance

  • Drugs Fasoracetam (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Adverse reactions
  • Most Recent Events

    • 17 Feb 2016 According to a Medgenics media release, data was presented at the 62nd American Academy of Child and Adolescent Psychiatry (AACAP) Annual Meeting
    • 11 Sep 2015 New trial record
    • 09 Sep 2015 Results will be presented at the 2015 American Academy of Child and Adolescent Psychiatry (AACAP) Annual Meeting, according to a Medgenics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top